JPH0432816B2 - - Google Patents

Info

Publication number
JPH0432816B2
JPH0432816B2 JP27674084A JP27674084A JPH0432816B2 JP H0432816 B2 JPH0432816 B2 JP H0432816B2 JP 27674084 A JP27674084 A JP 27674084A JP 27674084 A JP27674084 A JP 27674084A JP H0432816 B2 JPH0432816 B2 JP H0432816B2
Authority
JP
Japan
Prior art keywords
deifalanisole
culture
present
medium
chaetomium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP27674084A
Other languages
Japanese (ja)
Other versions
JPS61151149A (en
Inventor
Nobutaka Takahashi
Kenichi Asahi
Toshio Sakurai
Yasuhiro Iimura
Minoru Sanada
Hirobumi Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD KK
RIKEN
Original Assignee
Banyu Phamaceutical Co Ltd
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Phamaceutical Co Ltd, RIKEN filed Critical Banyu Phamaceutical Co Ltd
Priority to JP27674084A priority Critical patent/JPS61151149A/en
Publication of JPS61151149A publication Critical patent/JPS61151149A/en
Publication of JPH0432816B2 publication Critical patent/JPH0432816B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

(技術分野) 本発明は、新規な化合物デイフアラニソールA
(DifferanisoleA)及びその製造法に関するもの
である。 (発明の背景) 本発明者らは、分化・発生という生物学の最も
重要な問題の一つへの科学的アプローチを行うた
めに、従来より、内因性及び外因性の分化制御
能、特に分化誘導能を有する物質の探索とその科
学的研究を行つてきた。 そして、本発明者らが先に開発した簡便且つ再
現性のよい分化誘導物質の探索システムを用い
て、微生物の代謝産物や動物組織等の中に分化誘
導物質を求め、探索・精製・構造解析を行つた結
果、ケトミウム(Chaetomium)属に属する微生
物の培養物中に、フレンド白血病細胞に対して強
い分化誘導活性を示す文献未載の新規物質が産
生、蓄積されることの知見を得、その単離・精製
に成功した。 (発明の目的) 本発明の目的は、ケトミウム属に属する微生物
の培養物より得られる分化誘導活性物質デイフア
ラニソールAとその分離・採取方法を提供するこ
とにある。 (発明の構成) 〈使用する微生物〉 まず、本発明において用いる微生物は、デイフ
アラニソールAの生産能を有するものであり、ケ
トミウム属に属する菌種である。 その一例として、ケトミウム・エスピー・RB
−001(Chaetomium sp.RB−001)(以下、「RB
−001株」という。)と呼称される微生物が前記の
特性を有する菌株で、本発明のデイフアラニソー
ルAを有利に生産するものであり、本発明方法に
有効に利用し得る微生物として挙げられる。 又、上記RB−001株の自然的及び人工的変異
株はもちろん、ケトミウム属に属する菌種で、本
発明のデイフアラニソールAの生産能を有する微
生物は、すべて本発明方法において使用すること
ができる。 RB−001株は、本発明者により愛知県岡崎市
内で採取された土壌試料中より発見されたケトミ
ウム属に属する糸状菌であり、工業技術院・微生
物工業技術研究所に昭和59年12月22日に寄託さ
れ、その受託番号は、微工研菌寄第8021号
(FERM P−8021)である。 RB−001株の菌学的性質は、次の通りである。 1 各種寒天培地上の生育状態(27℃) (1) バレイシヨ・ブドウ糖寒天培地 生育は中程度で、初期には白色綿状で、14日
間培養ではクリーム色を帯びたビロードないし
毛状の菌糸が寒天上をおおい、黄オリーブ色の
頂毛を有する被子器が散在するようになる。培
養10日後頃より寒天中に褐色の色素が認められ
る。 (2) オートミール寒天培地 バレイシヨ・ブドウ糖寒天培地より生育は、
やや速く、白色綿毛状で密である。14日間培養
では、菌糸は白色から茶色に変わり、寒天中に
黄褐色の色素が認められる。被子器の着生も旺
盛であり、オリーブ色を呈す。 (3) サブロー寒天培地 菌糸の生育は極めて遅く、菌糸は白色で極め
て粗であり、1ケ月間培養でも被子器の形成は
みられない。 (4) セルロース寒天培地 生育は速く、14日間培養ではオリーブ色を呈
し、被子器を多数形成する。被子器の形成に較
べ、栄養菌糸は粗である。寒天中への色素生成
は認められない。 2 生理的性質 (1) 生育温度(バレイシヨ・ブドウ糖寒天培地) 10℃では菌糸の生育は殆んどなく、37℃では
菌糸の生育は非常に悪い。25〜30℃が栄養菌糸
の生育及び被子器の形成にとつて最適温度であ
る。 (2) 生育PH PH3.0以下、PH9.0以上では生育しない。 PH5.5〜7.0での生育が良好である。 3 顕微鏡による形態観察(27℃、バレイシヨ・
ブドウ糖寒天培地) 被子器は卵形に近い球形で、約300×250ミクロ
ンの大きさで頂端は開口し、多数の頂毛及び側毛
を有する。頂毛は螺線状で長くからみあつてお
り、隔壁を有し側毛はほぼ直線状となつている。
子のうは、8胞子性、棍棒状で無色であり、子の
う胞子はレモン状で大きさは9.0〜12.0×7.0〜9.0
ミクロンでオリーブ色を呈す。 上記諸性状を既知菌株のそれらと比較検討した
結果、L.M.Ames:A monograph of the
Chaetomiaceae.U.S.Army Res.Dev.Ser.No.2
(1961)及び宇田川俊一ほか著、1978年、無菌図
鑑、講談社発行等の文献に基づき、RB−001株
は、Rのう菌門該菌類、ケタマカビ科ケトミウム
属に属する菌株と同定された。 本発明に使用するケトミウム属に属し、デイフ
アラニソールA生産能を有する菌株の諸性質は一
定したものではなく、自然にあるいは通常行われ
る、例えば、紫外線照射、放射線照射や化学変異
剤などを用いる人工変異手段で変異しうるもので
あり、本発明で使用しうる菌株は、ケトミウム属
に属し、デイフアラニソールAを生産するすべて
の菌株を含むものである。 〈培養及び分離・精製〉 本発明における培養方法としては、微生物にお
ける通常の培養法に準じて行うことができる。 培地成分としては、例えば、炭素源として、グ
リコース、マルトース、シユクロース、糖密、グ
リセリン、セルロース、パウダー、皴、デキスト
リン、澱粉、大豆油、綿実油等が使用できる。
又、窒素源として大豆粉、落花生粉、綿実粉、魚
粉、コーン・スチーブリカー、ペプトン、肉エキ
ス、乾燥酵母、酵母エキス、カゼイン、硫酸アン
モニウム、硝酸アンモニウム、塩化アンモニウ
ム、硝酸ソーダ等が使用できる。その他必要に応
じて、マグネシウム、カリウム、ナトリウム、カ
ルシウム等の硫酸塩、塩酸塩、リン酸塩の他、微
量金属塩等も使用することができる。 培地は、通常液体培地が好ましく、培養は好気
的条件下で行うのが望ましい。培養温度、培養時
間等の条件は、使用菌の発育に適し、しかも、デ
イフアラニソールAの生産が最高になるような条
件が選ばれる。例えば、培地のPHは、弱酸性ない
し中性付近好ましくはPH6〜7、培養温度25〜30
℃が好ましい。 しかし、これらの培養組成物、培地の水素イオ
ン濃度、培養温度、攪拌条件などの培養条件は使
用する菌株の種類や、外部の条件などに応じて好
ましい結果が得られるように適宜調節されるべき
であることはいうまでもない。このようにして得
られる培養物から、デイフアラニソールAを得る
には、代謝産物を採取するのに通常用いられる手
段を適宜に利用することができる。たとえば、デ
イフアラニソールAと不純物との溶解度差を利用
する手段、吸着親和力の差を利用する手段のいず
れも、それぞれ単独で、または組合わせて、ある
いは反復して使用される。具体的には、デイフア
ラニソールAは培養液にその大部分が存在する
が、これから例えば、次の工程により分離・精製
を行うことができる。
(Technical field) The present invention provides a novel compound Deifalanisole A
(Differanisole A) and its manufacturing method. (Background of the Invention) In order to scientifically approach one of the most important problems in biology, which is differentiation and development, the present inventors have conventionally investigated the ability to control endogenous and extrinsic differentiation, particularly the ability to control differentiation. We have been searching for substances with induction ability and conducting scientific research on them. Then, using a simple and highly reproducible differentiation-inducing substance search system previously developed by the present inventors, we searched for differentiation-inducing substances in microbial metabolites, animal tissues, etc., and conducted search, purification, and structural analysis. As a result, we obtained the knowledge that a new substance, which has not yet been described in the literature, exhibits strong differentiation-inducing activity against Friend leukemia cells, is produced and accumulated in cultures of microorganisms belonging to the genus Chaetomium. Successful isolation and purification. (Object of the Invention) An object of the present invention is to provide a differentiation-inducing active substance Deifalanisole A obtained from a culture of a microorganism belonging to the genus Chaetomium, and a method for isolating and collecting the same. (Structure of the Invention) <Microorganisms Used> First, the microorganisms used in the present invention have the ability to produce Deifalanisole A, and are a species belonging to the genus Chaetomium. One example is Ketomium Sp. RB.
−001 (Chaetomium sp. RB−001) (hereinafter referred to as “RB
−001 shares.” ) is a strain having the above-mentioned characteristics, which advantageously produces the deifalanisole A of the present invention, and is mentioned as a microorganism that can be effectively used in the method of the present invention. In addition, not only natural and artificial mutant strains of the above-mentioned RB-001 strain, but also all microorganisms that belong to the genus Chaetomium and have the ability to produce Deifalanisole A of the present invention may be used in the method of the present invention. I can do it. Strain RB-001 is a filamentous fungus belonging to the genus Chaetomium that was discovered by the present inventor in a soil sample collected in Okazaki City, Aichi Prefecture. It was deposited on the 22nd, and its accession number is FERM P-8021. The mycological properties of the RB-001 strain are as follows. 1. Growth status on various agar media (27°C) (1) Potato/glucose agar medium Growth is medium, initially white cotton-like, and after 14 days of culture, cream-colored velvet or hair-like mycelia are formed. Covering the agar, angiospores with yellow-olive apical hairs become scattered. A brown pigment is observed in the agar after about 10 days of culture. (2) Growth from oatmeal agar medium and potato/glucose agar medium is as follows:
It is rather fast, white, fluffy and dense. After 14 days of culture, the hyphae turn from white to brown, and a yellow-brown pigment can be seen in the agar. The epiphytes of the angiosperms are also vigorous, giving the plant an olive color. (3) Sabouraud agar medium The growth of hyphae is extremely slow, the hyphae are white and extremely coarse, and no angiosperm formation is observed even after culturing for one month. (4) Cellulose agar medium It grows quickly, exhibits an olive color after 14 days of culture, and forms numerous angiosperms. The vegetative hyphae are coarse compared to the angiosperm formation. No pigment formation was observed in the agar. 2. Physiological Properties (1) Growth Temperature (Pallet/Glucose Agar Medium) At 10°C, there is almost no mycelial growth, and at 37°C, mycelial growth is very poor. 25-30°C is the optimal temperature for the growth of vegetative hyphae and the formation of angiosperms. (2) Growth PH: Will not grow below PH3.0 and above PH9.0. It grows well at pH 5.5 to 7.0. 3 Morphological observation using a microscope (27°C, Barley
Glucose agar medium) The angiosperm is spherical, close to oval, approximately 300 x 250 microns in size, open at the apex, and has numerous apical and lateral hairs. The apical hairs are long and spirally intertwined, with septa, and the lateral hairs are almost linear.
Asci are octosporous, club-shaped, and colorless; ascospores are lemon-shaped and size 9.0-12.0 x 7.0-9.0.
It has an olive color in micron size. As a result of comparing the above properties with those of known bacterial strains, LMAmes: A monograph of the
Chaetomiaceae.USArmy Res.Dev.Ser.No.2
(1961) and Shunichi Udagawa et al., 1978, Illustrated Guide to Sterility, published by Kodansha, etc., strain RB-001 was identified as a strain belonging to the phylum R. fungi, family Chaetomycota, genus Chaetomium. The properties of the strain belonging to the genus Chaetomium and having the ability to produce Deifalanisole A used in the present invention are not constant, and are exposed to natural or commonly used treatments such as ultraviolet irradiation, radiation irradiation, and chemical mutagens. Bacterial strains that can be mutated by the artificial mutation means used in the present invention belong to the genus Chaetomium and include all strains that produce Deifalanisole A. <Culture and Separation/Purification> The culturing method in the present invention can be carried out according to the usual culturing method for microorganisms. As the medium component, for example, as a carbon source, glycose, maltose, sucrose, molasses, glycerin, cellulose, powder, wrinkles, dextrin, starch, soybean oil, cottonseed oil, etc. can be used.
In addition, soybean flour, peanut flour, cottonseed flour, fish meal, corn steep liquor, peptone, meat extract, dried yeast, yeast extract, casein, ammonium sulfate, ammonium nitrate, ammonium chloride, sodium nitrate, etc. can be used as the nitrogen source. In addition to sulfates, hydrochlorides, phosphates of magnesium, potassium, sodium, calcium, etc., trace metal salts and the like can also be used as necessary. The medium is usually preferably a liquid medium, and the culture is preferably carried out under aerobic conditions. Conditions such as culture temperature and culture time are selected to be suitable for the growth of the bacteria used and to maximize the production of deifalanisole A. For example, the pH of the medium is slightly acidic to neutral, preferably PH6-7, and the culture temperature is 25-30.
°C is preferred. However, these culture conditions, such as the culture composition, hydrogen ion concentration of the medium, culture temperature, and stirring conditions, should be adjusted as appropriate to obtain favorable results depending on the type of bacterial strain used and external conditions. Needless to say, it is. In order to obtain deifalanisole A from the culture obtained in this manner, means commonly used for collecting metabolites can be appropriately used. For example, any of the means utilizing the solubility difference between Deifalanisole A and impurities and the means utilizing the difference in adsorption affinity may be used alone, in combination, or repeatedly. Specifically, most of Deifalanisole A is present in the culture solution, but from this it can be separated and purified, for example, by the following steps.

【表】 ↓
[Table] ↓

〔デイフアラニソールAの理化学的性質及び生物学的性質〕[Physicochemical and biological properties of Deifalanisole A]

(1) 融点:128℃ (2) 高分解能質量分析:(分子量)278 (分子式)C11H12O4Cl2 (3) 紫外線吸収スペクトル:(第1図のとおり) メタノール中、次の波長に極大吸収を示す。 (nm) (ε) 318 2700 257(肩) 4060 (4) 赤外線吸収スペクトル:(第2図のとおり) KBr中次の波数に特徴的な吸収帯を有する 3450,2995,2895,1675,1635,1560,
1463,1415,1365,1260,1225,1197,
1120,1085,1025,955,900,887,865,
825,778,758,720 cm-1 (5) 核磁気共鳴スペクトル(プロトン、CDCl3
400MHz):第3図のとおり。 (6) 核磁気共鳴スペクトル(13C,CD3OD,
100MHz):第4図のとおり。 (7) 溶解性:水、メタノール、アセトン、ジメチ
ルスルホキシド、ジメチルホルムア
ミドに可溶。 n−ヘキサン、石油エーテルに不
溶。 (8) 呈色反応: ヨウ素、過マンガン酸カリ反応 ……陽性 フエーリング液、2,4−ジニトロフエニル
ヒドラジン ……陰性 (9) 生物活性: 5μg/ml以上の濃度でマウスの赤血球性白血
病(B8)細胞に対し、分化誘導作用を示し、
20μg/mlで、B8細胞に対し、約40%ヘモグ
ロビンに誘導する。 上記の理化学的性質及びX線結晶解析から本発
明のデイフアラニソールAは、下記の構造式を有
する新規物質であると同定された。 〈デイフアラニソールAの構造式〉 デイフアラニソールAは、マウスの赤血球性白
血病細胞に対して分化誘導作用を示し、正常細胞
に誘導する作用を示すところから、抗腫瘍剤とし
ての利用が期待される。 以下に、本発明を実施例によつて詳述する。 実施例 (使用培地) シヨ糖 2% コーン・ステイープ・リカー 1% ペプトン 0.2% イースト 0.05% 食塩 0.1% K2HPO4 0.02% MgSO4・7H2O 0.05% (PH6.0) 〈フラスコ培養〉 上記培地100mlを500ml容平底フラスコに分注
し、120℃、30分間蒸気滅菌した後、RB−001株
(微工研菌寄第8021号)を接種し、27℃、3日間
往復振とう培養したものを種培養液とした。 同じ培地100mlを500ml容エーレンマイヤーフラ
スコに分注し、120℃、30分間蒸気滅菌したもの
に種培養液5mlを接種し、27℃、5〜7日間回転
振とう培養したものを本培養液とする。 〈ジヤーフアーメンター(30)培養〉 上記培地15を入れ、120℃、30分間蒸気滅菌
した後、フラスコ培養の種培養液1を接種し、
28℃で、4〜6日間通気攪拌培養する(回転数:
300r.p.m、通気量:15/分) 培養液を過後、液(13)を酸性条件下
(PH2.5)で酢酸エチル(9)を用いて2回抽出
した。 次いで、0.05M−トリス塩酸緩衝液(PH8.5)
に転溶し、再度、酢酸エチルを用い、酸性条件下
(PH2.5)で抽出を行つた。酢酸エチル層を濃縮
し、約10mlの濃縮液を得た。得られた濃縮液を、
シリカゲルカラムクロマトグラフイー(3.1〓×40
cm、展開溶媒CHCl3:CH3OH=9:1)に付
し、フレンド白血病細胞(mouse erythroid
leukemia cell,B8cell)を用いたアツセイ法に
よりチエツクしながら活性区分を分取した。これ
を更に、3.1〓×30cmのカラムを用いて同様にシリ
カゲルクロマトを行い、活性区分を分取した。得
られた活性区分を集め、ゲル過(担体;
Sephadex LH−20、カラム:1.5φ×30cm、展開
溶媒;0.05M酢酸塩緩衝液:メタノール=3:
7)を行い、前記アツセイ法によりチエツクしな
がら、活性区分を分取した。得られた活性画分を
濃縮し、酸性条件下(PH2.5)で酢酸エチルにて
抽出を行なつた。酢酸エチル層を濃縮して結晶を
得、更にメタノール−水(7:3)から再結晶を
行つて、デイフアラニソールAの無色針状晶17.0
mgを得た。
(1) Melting point: 128℃ (2) High-resolution mass spectrometry: (molecular weight) 278 (molecular formula) C 11 H 12 O 4 Cl 2 (3) Ultraviolet absorption spectrum: (as shown in Figure 1) In methanol, the following wavelengths shows maximum absorption. (nm) (ε) 318 2700 257 (shoulder) 4060 (4) Infrared absorption spectrum: (as shown in Figure 2) 3450, 2995, 2895, 1675, 1635, which has a characteristic absorption band at the middle wave number of KBr . 1560,
1463, 1415, 1365, 1260, 1225, 1197,
1120, 1085, 1025, 955, 900, 887, 865,
825, 778, 758, 720 cm -1 (5) Nuclear magnetic resonance spectra (protons, CDCl 3 ,
400MHz): As shown in Figure 3. (6) Nuclear magnetic resonance spectrum ( 13C , CD3OD ,
100MHz): As shown in Figure 4. (7) Solubility: Soluble in water, methanol, acetone, dimethyl sulfoxide, and dimethyl formamide. Insoluble in n-hexane, petroleum ether. (8) Color reaction: Iodine, potassium permanganate reaction...Positive Fehring's solution, 2,4-dinitrophenylhydrazine...Negative (9) Biological activity: At concentrations of 5 μg/ml or higher, erythroid leukemia ( B8) Shows a differentiation-inducing effect on cells,
At 20 μg/ml, approximately 40% hemoglobin is induced in B8 cells. Deifalanisole A of the present invention was identified as a novel substance having the following structural formula from the above-mentioned physicochemical properties and X-ray crystal analysis. <Structural formula of Deifalanisole A> Deifalanisole A is expected to be used as an antitumor agent because it exhibits a differentiation-inducing effect on mouse erythroid leukemia cells and an effect on inducing normal cells. The present invention will be explained in detail below by way of examples. Examples (Medium used) Sugar 2% Corn steep liquor 1% Peptone 0.2% Yeast 0.05% Salt 0.1% K 2 HPO 4 0.02% MgSO 4.7H 2 O 0.05% (PH6.0) <Flask culture> Above 100 ml of the culture medium was dispensed into a 500 ml flat-bottomed flask and steam sterilized at 120°C for 30 minutes, then inoculated with RB-001 strain (Feikoken Bacteria No. 8021) and cultured at 27°C for 3 days with reciprocal shaking. This was used as the seed culture solution. Dispense 100 ml of the same medium into a 500 ml Erlenmeyer flask, steam sterilize it at 120°C for 30 minutes, inoculate it with 5 ml of the seed culture, culture it with rotary shaking at 27°C for 5 to 7 days, and use it as the main culture. do. <Jafer Armenter (30) Culture> Add the above medium 15, steam sterilize at 120°C for 30 minutes, then inoculate with flask culture seed culture solution 1.
Culture with aeration at 28°C for 4 to 6 days (rotation speed:
After passing through the culture solution, the solution (13) was extracted twice with ethyl acetate (9) under acidic conditions (PH2.5). Next, 0.05M-Tris-HCl buffer (PH8.5)
The mixture was extracted with ethyl acetate under acidic conditions (PH2.5). The ethyl acetate layer was concentrated to obtain about 10 ml of a concentrated solution. The obtained concentrate is
Silica gel column chromatography (3.1〓×40
Friend leukemia cells ( mouse erythroid
The active fraction was collected while checking using an assay method using leukemia cell (B8cell). This was further subjected to silica gel chromatography in the same manner using a 3.1×30 cm column, and the active fraction was fractionated. The obtained active fractions were collected and subjected to gel filtration (carrier;
Sephadex LH-20, column: 1.5φ x 30cm, developing solvent: 0.05M acetate buffer: methanol = 3:
7) was carried out, and the active fraction was fractionated while being checked by the above-mentioned assay method. The obtained active fraction was concentrated and extracted with ethyl acetate under acidic conditions (PH2.5). The ethyl acetate layer was concentrated to obtain crystals, which were further recrystallized from methanol-water (7:3) to obtain colorless needle-like crystals of Deifalanisole A (17.0%).
I got mg.

【図面の簡単な説明】[Brief explanation of drawings]

第1図は、本発明のデイフアラニソールAの紫
外線吸収スペクトルを、第2図は、デイフアラニ
ソールAの赤外線吸収スペクトルを、第3図は、
デイフアラニソールAの核磁気共鳴スペクトル
(プロトン)を、第4図は、デイフアラニソール
Aの核磁気共鳴スペクトル(13C)をそれぞれ示
す図面である。
Figure 1 shows the ultraviolet absorption spectrum of Deifalanisole A of the present invention, Figure 2 shows the infrared absorption spectrum of Deifalanisole A, and Figure 3 shows the infrared absorption spectrum of Deifalanisole A of the present invention.
FIG. 4 is a diagram showing the nuclear magnetic resonance spectrum (proton) of deifalanisole A, and FIG. 4 shows the nuclear magnetic resonance spectrum ( 13 C) of deifalanisole A.

Claims (1)

【特許請求の範囲】 1 構造式: で示されるデイフアラニソール(Differanisole)
A。 2 ケトミウム(Chaetomium)属に属するデイ
フアラニソールA生産菌を培養し、その培養物よ
りデイフアラニソールAを分離・採取することを
特徴とするデイフアラニソールAの製造法。 3 ケトミウム属に属するデイフアラニソールA
生産菌がケトミウム・エスピー・RB−001
(Chaetomium sp.RB−001)(FERM P−8021)
である特許請求の範囲第2項記載の製造法。
[Claims] 1 Structural formula: Differanisole denoted by
A. 2. A method for producing deifalanisol A, which comprises culturing deifalanisole A-producing bacteria belonging to the genus Chaetomium, and separating and collecting deifalanisol A from the culture. 3 Deifalanisole A belonging to the genus Chaetomium
The producing bacterium is Chaetomium sp. RB-001
(Chaetomium sp.RB-001) (FERM P-8021)
The manufacturing method according to claim 2.
JP27674084A 1984-12-26 1984-12-26 Differanisole a and its preparation Granted JPS61151149A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP27674084A JPS61151149A (en) 1984-12-26 1984-12-26 Differanisole a and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27674084A JPS61151149A (en) 1984-12-26 1984-12-26 Differanisole a and its preparation

Publications (2)

Publication Number Publication Date
JPS61151149A JPS61151149A (en) 1986-07-09
JPH0432816B2 true JPH0432816B2 (en) 1992-06-01

Family

ID=17573677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP27674084A Granted JPS61151149A (en) 1984-12-26 1984-12-26 Differanisole a and its preparation

Country Status (1)

Country Link
JP (1) JPS61151149A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109971655B (en) * 2019-04-12 2021-01-22 山东第一医科大学(山东省医学科学院) A strain of Chaetomium sp. HQ-1 and its application

Also Published As

Publication number Publication date
JPS61151149A (en) 1986-07-09

Similar Documents

Publication Publication Date Title
KR830002329B1 (en) Preparation of monacolin k.
JPH09505567A (en) Polycyclic anthelmintic drug, method and strain for producing the same, and use thereof
JPH02231071A (en) Microbiological preparation of immunosuppressive antibiotic
DE68906825T2 (en) Glycoside antibiotics BU-3608D and BU-3608E.
EP0196628A2 (en) Ansamycin antibioticum, microbiological process for its preparation and its use as a medicament
DE69604385T2 (en) ISOCUMARINE WITH ANTITUARY EFFECT
JPH0432816B2 (en)
DE3444184A1 (en) ANTIBIOTIC EM 5487
US4382952A (en) Antibiotic roridin L-2 and its use
EP0304400B1 (en) Phenanthridine derivatives, process for their preparation and medium for performing the process
EP0026485B1 (en) Herbicoline, process for its preparation and compositions containing it
DE69823866T2 (en) SUBSTANCE FT-0554 AND METHOD FOR THE PRODUCTION THEREOF
JPH08502406A (en) Antibiotics
DE69902537T2 (en) A CONNECTION, WF002, A METHOD FOR THEIR PRODUCTION AND THEIR USE
JPS59120095A (en) Antibiotic oxirapentyn and its preparation
JP2815166B2 (en) New antibiotic MK1688 and its production
JPS6265692A (en) Production of leptomycin a
JP4235298B2 (en) Antibiotic pareic acid A and its production method
JPS58209986A (en) Antibiotic substance fosfonochlorin and its preparation
JPH0680607A (en) Malbranicin
WO1997036921A1 (en) Antifungal peptides from scleroderma texense
JPH06135979A (en) New substance nk374200, its production and use thereof
JPH01312994A (en) Antimycotic substance yi-hu1 and production thereof
JPS6241516B2 (en)
JPS6143182A (en) Novel antibiotic ss19508d and preparation thereof

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees